Skip to main content
Clinical Trials/NCT00231062
NCT00231062CompletedPhase 3

Clinical Evaluation to Confirm Safety and Efficacy of Sinuplasty in the Paranasal Sinuses (CLEAR)

Integra LifeSciences Corporation0 sites115 target enrollmentStarted: April 2005Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
115
Primary Endpoint
Number of Sinuses With Patency of Sinus Ostium After Sinuplasty

Study Overview

Brief Summary

A multi-center, non-randomized, prospective post-market evaluation of sinuplasty in paranasal sinuses.

Detailed Description

Sinusitis is a common healthcare problem that significantly reduces quality of life for people around the world. Patients suffer from headache, facial discomfort, nasal congestion, nasal drainage, loss of the sense of smell and malaise. Sinusitis is responsible for major healthcare expenditure and loss of workplace productivity.

The rationale of this study is to collect data on the effectiveness and safety of balloon dilation of the Frontal, Maxillary and Sphenoid sinuses by treating patients and observing them for a six month period of time following the procedure. Six month follow-up data is important to demonstrate the effectiveness of balloon catheter dilation.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age 18 years and greater
  • Both male and female patients eligible
  • Diagnosis of chronic sinusitis that is not responsive to medical management
  • Planned endoscopic sinus surgery (recommended by PI, consented to by patient)

Exclusion Criteria

  • Extensive sinonasal polyps
  • Extensive previous sinonasal surgery
  • Extensive sinonasal osteoneogenesis
  • Cystic fibrosis
  • Sampter's Triad (Aspirin sensitivity, Asthma, Sinonasal polyposis)
  • Sinonasal tumors or obstructive lesions
  • History of facial trauma that distorts sinus anatomy and precludes access to the sinus ostium
  • Ciliary dysfunction
  • Pregnant females

Outcomes

Primary Outcomes

Number of Sinuses With Patency of Sinus Ostium After Sinuplasty

Time Frame: 24 weeks

Patency of sinus ostium after sinuplasty will be determined by nasal endoscopic examination. The investigator will make a clinical judgment as to whether or not this has been achieved.

Number of Participants With Adverse Events Following Sinuplasty Procedure

Time Frame: 24 weeks

Adverse event rate at 24 weeks: comprised of all observed peri-operative adverse events which were recorded on dedicated CRFs and any observed or patient-reported post-operative adverse events will be similarly recorded (through 24 week follow-up).

Secondary Outcomes

  • Number of Participants Experiencing Relief of Sinus Symptoms(Week 24)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials